Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.79 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.76 |
| ▸ | MPO | P05164 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | NQO2 | P16083 | 1/20 | 0.76 |
| ▸ | HTR2B | P41595 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.76 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5612765 | 0.89 | MTNR1A (0.80) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL29524586 | 0.89 | MTNR1A (0.80) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL19261961 | 0.88 | MTNR1A (0.80) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL32678246 | 0.88 | MTNR1A (0.79) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL7794072 | 0.88 | MTNR1A (0.79) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL7794006 | 0.88 | MTNR1A (1.00) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL5616635 | 0.88 | MTNR1A (0.85) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL7794103 | 0.88 | MTNR1A (0.79) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL23644935 | 0.86 | MTNR1A (0.83) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| Melatonin SCHEMBL4686085 | 0.86 | MTNR1A (1.00) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339423-A1 | METHODS FOR TREATING NEUTROPENIA | X4 PHARMACEUTICALS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250248991-A1 | METHODS FOR TREATING NEUTROPENIA | X4 PHARMACEUTICALS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12377090-B1 | Methods for treating neutropenia | X4 PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | ALPHA-9 ONCOLOGY INC. (CA) | 2025-07-31 | — | — | US | disclosed |
| US-20250152575-A1 | METHODS FOR TREATING IMMUNODEFICIENCY DISEASE | X4 PHARMACEUTICALS, INC. | 2025-05-15 | — | — | US | disclosed |
| US-12285424-B2 | Methods for treating neutropenia | X4 PHARMACEUTICALS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| EP-4511384-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | Provincial Health Services Authority (CA) | 2025-02-26 | — | — | EP | disclosed |
| US-20240100203-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-03-28 | — | — | US | disclosed |
| US-20240082346-A1 | Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same | MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD. (CN) | 2024-03-14 | — | — | US | disclosed |
| US-11883501-B2 | Selective CXCR4 binding peptide conjugate and methods for making and using the same | MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD. (CN) | 2024-01-30 | — | — | US | disclosed |
| US-11771736-B2 | Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same | MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| EP-4232459-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | Provincial Health Services Authority (CA) | 2023-08-30 | — | — | EP | disclosed |
| US-20230014231-A1 | METHODS FOR TREATING NEUTROPENIA | X4 PHARMACEUTICALS, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-4117662-A1 | METHODS FOR TREATING NEUTROPENIA | X4 Pharmaceuticals, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| CN-115515585-A | Methods for treating neutropenia | X4 制药有限公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-4097120-A1 | ISOTOPICALLY LABELLED SELECTIVE CXCR4 BINDING PEPTIDE CONJUGATE AND METHODS FOR MAKING AND USING THE SAME | Mainline Biosciences LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3393468-B1 | METHODS FOR TREATING IMMUNODEFICIENCY DISEASE | X4 PHARMACEUTICALS INC (US) | 2022-09-14 | — | — | EP | disclosed |
| US-20220257586-A1 | METHODS FOR TREATING IMMUNODEFICIENCY DISEASE | X4 PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20220218852-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-07-14 | — | — | US | disclosed |
| WO-2022082312-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | CXCR4, CXCL12, ACKR3 | MTNR1A 1328/4885MTNR1B 929/4885KMT2A 4385/4885 |
| US-11883501-B2 | Selective CXCR4 binding peptide conjugate and methods for making and using the same | CXCR4, CXCR1, ACKR3 | MTNR1A 1616/4885MTNR1B 1494/4885KMT2A 3119/4885 |
| US-20240100203-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | CXCR4, CXCL12, CXCR2 | MTNR1A 1418/4885MTNR1B 878/4885KMT2A 4432/4885 |
| US-20220257586-A1 | METHODS FOR TREATING IMMUNODEFICIENCY DISEASE | CXCR4, CXCL12, CCR5 | MTNR1A 946/4885MTNR1B 745/4885KMT2A 1343/4885 |
| US-12377090-B1 | Methods for treating neutropenia | CSF3R, CSF1R, NCF1 | MTNR1A 289/4885MTNR1B 163/4885KMT2A 672/4885 |
| US-20220218852-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | CXCR4, CXCR1, FPR1 | MTNR1A 414/4885MTNR1B 553/4885KMT2A 3303/4885 |
| US-20250248991-A1 | METHODS FOR TREATING NEUTROPENIA | CSF3R, CSF1R, NCF1 | MTNR1A 289/4885MTNR1B 163/4885KMT2A 672/4885 |
| US-20250339423-A1 | METHODS FOR TREATING NEUTROPENIA | CSF3R, CSF1R, NCF1 | MTNR1A 289/4885MTNR1B 163/4885KMT2A 672/4885 |
| US-20230014231-A1 | METHODS FOR TREATING NEUTROPENIA | CSF3R, CSF1R, NCF1 | MTNR1A 289/4885MTNR1B 163/4885KMT2A 672/4885 |
| US-11771736-B2 | Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same | CXCR4, CXCR3, CXCR1 | MTNR1A 1593/4885MTNR1B 1417/4885KMT2A 2796/4885 |
| US-12285424-B2 | Methods for treating neutropenia | CSF3R, CSF1R, NCF1 | MTNR1A 289/4885MTNR1B 163/4885KMT2A 672/4885 |
| US-20250152575-A1 | METHODS FOR TREATING IMMUNODEFICIENCY DISEASE | CXCR4, CXCL12, CCR5 | MTNR1A 946/4885MTNR1B 745/4885KMT2A 1343/4885 |
| US-20240082346-A1 | Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same | CXCR4, CXCR3, CXCR1 | MTNR1A 1564/4885MTNR1B 1404/4885KMT2A 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.